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Background: Aberrant methylation of genes is one of the most common epigenetic modifications involved in the
development of urothelial carcinoma. However, it is unknown the predictive role of methylation to contralateral new
upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). We retrospectively investigated the
predictive role of DNA methylation and other clinicopathological factors in the contralateral upper tract urothelial
carcinoma (UTUC) recurrence after radical nephroureterectomy (RNU) in a large single-center cohort of patients.
Methods: In a retrospective design, methylation of 10 genes was analyzed on tumor specimens belonging to 664
consecutive patients treated by RNU for primary UTUC. Median follow-up was 48 mo (range: 3–144 mo). Gene
methylation was accessed by methylation-sensitive polymerase chain reaction, and we calculated the methylation
index (MI), a reflection of the extent of methylation. The log-rank test and Cox regression were used to identify the
predictor of contralateral UTUC recurrence.
Results: Thirty (4.5%) patients developed a subsequent contralateral UTUC after a median follow-up time of 27.5
(range: 2–139) months. Promoter methylation for at least one gene promoter locus was present in 88.9% of UTUC.
Fewer methylation and lower MI (P = 0.001) were seen in the tumors with contralateral UTUC recurrence than the
tumors without contralateral recurrence. High MI (P = 0.007) was significantly correlated with poor cancer-specific
survival. Multivariate analysis indicated that unmethylated RASSF1A (P = 0.039), lack of bladder recurrence prior to
contralateral UTUC (P = 0.009), history of renal transplantation (P < 0.001), and preoperative renal insufficiency
(P = 0.002) are independent risk factors for contralateral UTUC recurrence after RNU.
Conclusions: Our data suggest a potential role of DNA methylation in predicting contralateral UTUC recurrence
after RNU. Such information could help identify patients at high risk of new contralateral UTUC recurrence after
RNU who need close surveillance during follow up.
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Upper tract urothelial carcinoma (UTUC) accounts for
about 5-10% of all urothelial carcinomas [1]. The standard
treatment of upper tract urothelial carcinoma (UTUC)
is radical nephroureterectomy (RNU) with bladder cuff
excision [2]. Although the development of contralateral
UTUC after RNU is relatively rare with an estimated inci-
dence of 0.8-6% [3-12], the risk of consequent renal func-
tion compromise can be very grave, resulting in the need
for dialysis. Few studies are available concerning the risk
factors for predicting the development of metachronous
contralateral UTUC [3-7]. These studies are limited by
small sample sizes or unclear enrollment criteria, and only
focusing on clinicopathological factors, it is conceivable
that even tumors with identical clinicopathological charac-
teristics could behave differently. A growing body of evi-
dence indicates that aberrant methylation of cytosine-
guanine dinucleotide (CpG) islands in the DNA promoter
regions is one of the most common epigenetic modifica-
tions involved in the development of urothelial carcinoma
[13-17]. Detecting gene promoter methylation may be a
promising method for predicting contralateral UTUC
recurrence after surgery.
Our previous study has demonstrated that renal trans-
plant history and renal insufficiency are independent risk
factors [3]. We updated the database and evaluated the
methylation status of specific genes in UTUC in order to
elucidate their value in predicting contralateral UTUC
recurrence. Previous studies confirmed that TMEFF2,
VIM and GDF15 were proved highly methylated level in
UTUC, but the predictive role of them were not com-
pletely understood for the small sample size [17]. THBS1
is a known angiogenesis inhibitor associated with neo-
vascularization in human cancer [18], its expression as-
sociated with tumor malignance in UTUC [19]. Because
bladder urothelial carcinoma and UTUC both derive
from the urothelial cell and show genomic and clinical
similarities [20]. We chosen another six epigenetic bio-
markers that accurately detect bladder cancer, including
SALL3, ABCC6, RASSF1A, BRCA1, CDH1 and HSPA2
[15,16]. Finally, we selected the above 10 genomic re-
gions wih CpG islands to investigate the predictive role
in new contralateral UTUC after RNU. To our know-
ledge, we are the first group to investigate the corre-
lation between metachronous contralateral UTUC and
gene methylation.
Methods
Patient selection
We retrospectively reviewed the records of 820 consecu-
tive patients from Peking University First Hospital
(Beijing, China) who underwent surgery for UTUC from
1999 to 2011. Of this cohort, 156 patients were excluded
from the study: 76 for concomitant or previous bladdertumor, 30 for bilateral UTUCs, 23 for undergoing nephron-
sparing surgery instead of RNU, and 27 for inability to
extract DNA as there was only one paraffin specimen
stored in our bank. 664 patients were ultimately included
for evaluation. No patients with solitary kidney or vesi-
coureteral reflux were discovered in this cohort. No pa-
tients received neoadjuvant chemotherapy or prophylactic
postoperative intravesical instillation chemotherapy, al-
though adjuvant chemotherapy or radiotherapy was ad-
ministered to some patients when evidence of metastasis
or retroperitoneal recurrence was discovered.
Patient evaluation
In this cohort, UTUC was diagnosed by computed tomog-
raphy (CT), magnetic resonance imaging (MRI), urologic
ultrasound, or ureteroscopy with or without biopsy. The
contralateral upper tract was evaluated to exclude bilateral
carcinoma involvement. Ipsilateral hydronephrosis was
determined by ultrasound, MRI, or CT before operation.
Based on the site of the dominant lesion, tumor location
was divided into renal pelvic tumors and ureteral tumors,
where ureteral tumors were further subdivided into the
upper ureter (superior to the sacrum), the middle ureter
(between the upper and the lower borders of the sacrum),
and the lower ureter (inferior to the sacrum) [21]. The
preoperative estimated glomerular filtration rate (eGFR)
was evaluated by the modified estimating equation of
glomerular filtration rate for Chinese patients [eGFR
(ml/min/1.73 m2) = 175 × Scr− 1.234 × age− 0.179 (×0.79 for
female)] [22].
All surgical specimens were reviewed by two senior pa-
thologists who were blinded to the patients’ personal data.
Tumor stage was classified based on the 2002 UICC
TNM classification of malignant tumors. Histological
grades were assessed based on the WHO classification of
1973. Tumor architecture was divided into papillary and
sessile groups. Tumor multifocality was described as the
simultaneous existence of two or more pathologically vali-
dated macroscopic tumors from any location.
Methylation analyses of gene promoters
Eight 5-um-thick sections were obtained from formalin-
fixed paraffin-embedded tumor tissue, DNA was extracted
from them containing >70% tumor using the QIAamp
DNA FFPE Tissue Kit (Qiagen, Hilden, Germany). For
bisulfite transformation, approximately 1.5 μg tumor
DNA was treated with sodium bisulfite using EpiTect Fast
Bisulfite Conversion Kits (Qiagen, Hilden, Germany).
Sample processing was performed according to the manu-
facturer’s protocol. Methylation-sensitive polymerase
chain reaction was performed using approximate 50 ng of
converted DNA to analyze the methylation status of the
10 gene promoters, as previously described by Herman
et al. [23]. We performed PCR for methylated and also
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mers used for each gene is shown in Table 1. We used
commercially available methylated human genomic DNA
(Qiagen, Hilden, Germany) as positive control, and we
used water blanks and PCR mixtures as negative control.
Because a low prevalence of hypermethylation for all
these gene promoters was validated in normal tissue
[13-16,24], we did not compare the methylation status
between UTUC and normal tissue any further in our
study. As previous described [14], the extent of methyla-
tion for each tumor was calculated by a methylation
index (MI; the ratio of number of methylated genes/total
number of analyzed genes).
Postoperative follow-up
Postoperative follow-up consisted of history, physical
examination, urinalysis, serum creatinine, urine cytology
(and/or urine fluorescence in situ hybridization), chest
x-ray, cystoscopy, and ultrasound or CT/MRI. The follow-
up interval was every 3 months for the first 2 years and
yearly thereafter at our institute.
Contralateral UTUC after RNU was defined as urothelial
carcinoma in the contralateral upper urinary tract detected
on imaging or confirmed by pathological evaluation. The
endpoint of this study was the first detection of contrala-
teral UTUC or, for patients who did not develop such an
outcome, the date of last follow-up or death.Table 1 Primer sequences for MSP
Gene Sense 5'→3' Antisense 5'→3’
ABCC6 M GGCGTTCGGGGAGTT CGACCTCGACCCGA
ABCC6 U AGGTGTTTGGGGAGTTGG TCTCAACCTCAACCC
BRCA1 M TCGTGGTAACGGAAAAGCGC AAATCTCAACGAACT
BRCA1 U TTGGTTTTTGTGGTAATGGAAAAGTGT CAAAAAATCTCAACA
CDH1 M GTGGGCGGGTCGTTAGTTTC CTCACAAATACTTTA
CDH1 U GGTGGGTGGGTTGTTAGTTTTGT AACTCACAAATCTTT
GDF15 M CGGCGGTTATTTGTATTTGC AACGATCGTATCACG
GDF15 U ATTTGGTGGTTATTTGTATTTGT AACAATCATATCACA
HSPA2 M TAAGAATCGGGAATTGGGC AATCGATACCGATAA
HSPA2 U TTATAAGAATTGGGAATTGGGT AAATCAATACCAATA
RASSF1A M GGGTTTTGCGAGAGCGCG GCTAACAAACGCGA
RASSF1A U GGTTTTGTGAGAGTGTGTTTAG CACTAACAAACACA
SALL3 M GTTCGCGTAGTCGTCGTC TACTCGAAAACCCCG
SALL3 U GTGGTTTGTGTAGTTGTTGTTGTT CCCAACCCTCACCAT
THBS1 M TGCGAGCGTTTTTTTAAATGC TAAACTCGCAAACCA
THBS1 U GTTTGGTTGTTGTTTATTGGTTG CCTAAACTCACAAAC
TMEFF2 M GAAGAGGGGCGTTAGTTC ACGCTAACCCGAATA
TMEFF2 U GGAAGAGGGGTGTTAGTT AACACTAACCCAAA
VIM M TTATAAAAATAGCGTTTTCGGC ATAACGCGAACTAAC
VIM U GGGTTATAAAAATAGTGTTTTTGGT ACAATAACACAAACStatistical analysis
Categorical data was analyzed using Pearson’s chi-squared
test. Continuous data were analyzed using the Mann–
Whitney U test and Kruskal-Wallis H test. Log-rank tests
were used for univariate analysis, and Cox’s proportional
hazards regression model was used for multivariate ana-
lysis. Only variables identified as significant by univariate
analysis were analyzed in a multivariate fashion. Statis-
tical analysis was performed using SPSS 20.0 (IBM, Corp,
Armonk, NY, USA). P value <0.05 was regarded as
significant.Results
Overall results of Clinical follow-up
All 664 patients included were proven to have UTUC
pathologically. The patients’ demographic and histological
data are presented in Table 2. The median age of our co-
hort was 68 years (range 20–90). The median follow-up
period was 48 months (range 3–144). Thirty (4.5%) pa-
tients developed a subsequent contralateral UTUC after a
median follow-up time of 27.5 (range: 2–139) months.
The 5-year probability of freedom from contralateral
metachronous UTUC was 95%. The mean contralateral
UTUC-free survival period was 136 ± 1.488 months. 223
patients (33.6%) developed bladder recurrence. 214 pa-
tients (32.2%) died of urothelial cancer after a medianAnnealing temperature (°C) Product size (bp)
TAAT 57 247
AATAATC 58 244
CACGCC 58 75
AACTCACACCA 56 86
CAATTCCGACG 57 172
ACAATTCCAAC 59 172
TCCC 60 132
TCCCACA 57 135
CCGAA 58 172
ACCAAA 55 176
ACCG 64 169
AACCAAAC 59 169
TCA 57 203
ACTC 57 220
ACTCG 62 74
CAACTCA 62 115
AAACT 57 151
TAAAACT 55 153
TCCCG 59 143
TAACTCCCA 56 149
Table 2 Patient demographic and histological data
Variables N (%)
Gender
Male 295 (44.4)
Female 369 (55.6)
Age
<70 372 (56.0)
≥70 292 (44.0)
Preoperative renal function
eGFR≥ 60 298 (44.9)
60 >eGFR≥15 316 (47.6)
eGFR <15 50 (7.5)
Side
Left 326 (49.1)
Right 338 (50.9)
Transplant recipient
No 653 (98.3)
Yes 11 (1.7)
Ipsilateral hydronephrosis
Absence 290 (43.7)
Presence 374 (56.3)
Tobacco consumption
No 543 (81.8)
Yes 121 (18.2)
Surgical approach
Open 445 (67.0)
Laparoscopic 219 (33.0)
Tumor size
≤3 cm 373 (56.2)
>3 cm 291 (43.8)
Architecture
Papillary 515 (77.6)
Sessile 149 (22.4)
Ureteroscopy
No 583 (87.8)
Yes 81 (12.2)
Location
Pelvis 368 (55.4)
Ureter 296 (44.6)
Upper ureter 58 (8.7)
Middle ureter 68 (10.2)
Lower ureter 170 (25.6)
Multifocality
No 505 (76.1)
Yes 159 (23.9)
Table 2 Patient demographic and histological data
(Continued)
CIS
Absence 645 (97.1)
Presence 19 (2.9)
Contralateral recurrence
No 634 (95.5)
Yes 30 (4.5)
Bladder recurrence
No 441 (66.4)
Yes 223 (33.6)
Before contralateral UTUC 209 (31.5)
Concomitant and after contralateral UTUC 14 (2.1)
Tumor stage
Ta or T1 221 (33.3)
T2 237 (35.7)
T3 194 (29.2)
T4 12 (1.8)
Tumor grade
G1 21 (3.2)
G2 360 (54.2)
G3 283 (42.6)
N status
N+ 47 (7.1)
cN0 or pN0 617 (92.9)
Adjuvant therapy
No 641 (96.5)
Yes 23 (3.5)
eGFR = estimated glomerular filtration rate; CIS = carcinoma in situ;
UTUC = upper tract urothelial carcinoma.
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survival period was 115 months (95% CI, 99–130 months).
CpG island Methylation for UTUC
Aberrant methylation for at least one gene promoter
locus was detected in 88.9% of all DNA samples. For all
loci, more frequent methylation was present in patients
without contralateral UTUC recurrence than patients
with contralateral recurrence with statistical significance
achieved for RASSF1A (P = 0.012) and VIM (P = 0.006).
The methylation rate of RASSF1A is 27.4% (174/634
cases) in patients without contralateral UTUC recur-
rence, and only 6.7% (2/30 cases) in patients with
contralateral UTUC recurrence. For VIM, the methyla-
tion rate is 64.7% (410/634) in patients without con-
tralateral UTUC recurrence, and 40% (12/30 cases) in
patients with contralateral UTUC recurrence. The fre-
quency of methylation for each gene and the correlation
between methylation and patients characteristics were
Table 3 Summary of the frequency of methylation of the genes in UTUC based on the main clinicopathologic variables
Overall
methylation
(%) n = 664
Age, % Gender, % Architecture, % Tumor size, % Multifocal, % Smoke, % Stagea, % Gradeb, %
<70
n = 372
≥70
n = 292
Male
n = 295
Female
n = 369
Papillary
n = 515
Sessile
n = 149
≤3 cm
n = 373
>3 cm
n = 291
Yes
n = 159
No
n = 505
Yes
n = 121
No
n = 543
Low stage
n = 458
High stage
n = 206
Low grade
n = 381
High stage
n = 283
ABCC6 14.5 12.6 16.8 11.5 16.8 12.8 20.1 13.7 15.5 11.3 15.4 9.9 15.5 12.7 18.4 12.6 17.0
BRCA1 17.2 17.2 17.1 12.5 20.9 14.0 28.2 16.4 18.2 20.1 16.2 9.9 18.8 15.1 21.8 13.4 22.3
CDH1 14.2 13.2 15.4 14.2 14.1 11.7 22.8 14.5 13.7 11.9 14.9 15.7 13.8 11.6 19.9 10.5 19.1
GDF15 49.2 48.4 50.3 53.2 46.1 52.4 38.3 46.4 52.9 49.7 49.1 55.4 47.9 45.6 57.3 54.3 42.4
HSPA2 41.6 38.4 45.5 40.0 42.8 39.0 50.3 39.9 43.6 38.4 42.6 37.2 42.5 35.2 55.8 37.3 47.3
RASSF1A 26.5 26.1 27.1 25.4 27.4 27.4 32.9 24.1 29.6 20.1 28.5 19.8 27.8 22.9 34.0 22.8 31.1
SALL3 34.6 33.3 36.3 33.2 35.8 33.4 39.6 35.1 34.0 30.8 35.8 26.4 36.5 32.8 38.8 33.3 36.4
THBS1 25.2 22.8 28.1 26.4 24.1 20.7 40.3 27.6 22.0 21.4 26.3 26.6 24.9 22.5 31.1 19.2 33.2
TMEFF2 43.4 41.1 46.2 43.4 43.4 41.7 49.0 38.3 49.8 37.7 45.1 41.3 43.8 39.3 52.4 40.4 47.3
VIM 63.6 59.1 69.2 66.4 61.2 63.5 63.8 60.6 67.4 61.6 64.2 66.1 63.0 61.4 68.4 64.0 62.9
aThe stage was divided into a low stage (stage Ta, T1, or T2) group and a high stage (stage T3 or T4) group.
bThe grade was divided into a low grade (grade G1 or G2) group and a high grade (grade G3) group.
The data reaching for statistical significance was present in bold type.
The methylation of VIM (P = 0.008), BRCA1 (P = 0.005), TMEFF2 (P = 0.003), and RASSF1A (P = 0.037) was correlated with the age, gender, tumors size, and mulifocality, respectively. The methylation of BRCA1 (P = 0.019)
and SALL3 (P = 0.036) were correlated with smoke history. The methylation of ABCC6 (P = 0.025), BRCA1 (P = 0.000), CDH1 (P = 0.001), GDF15 (P = 0.002), HSPA2 (P = 0.014), RASSF1A (P = 0.045), and TSHB1 (P = 0.000)
was correlated with the architecture of tumors. Methylation was associated with advanced tumor grade for BRCA1 (P = 0.003), CDH1 (P = 0.002), HSPA2 (P = 0.009), RASSF1A (P = 0.017), and THBS1 (P = 0.000), and
unmethylated GDF15 (P = 0.002) promoter was associated with advanced tumor grade. Methylation was associated with advanced tumor stage for ABCC6 (P = 0.050), BRCA1 (P = 0.032), CDH1 (P = 0.004), GDF15
(P = 0.005), HSPA2 (P = 0.000), RASSF1A (P = 0.003), TSHB1 (P = 0.018), and TMEFF2 (P = 0.002).
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Table 4 MI based on the clinicopathological factors
No. of
patients
MI P
Mean SD
Contralateral recurrence 0.001*
No 634 0.3361 0.22882
Yes 30 0.1967 0.19025
Grade <0.001*
G1 21 0.1667 0.14606
G2 360 0.3161 0.22121
G3 283 0.3594 0.23732
Stage <0.001*
Ta or T1 221 0.3009 0.21062
T2 237 0.2975 0.21803
T3 194 0.3964 0.24629
T4 12 0.4250 0.24541
N status 0.014*
cN0 or pNo 617 0.3241 0.22860
N+ 47 0.4043 0.22259
Architecture 0.001*
Papillary 515 0.3140 0.22534
Sessile 149 0.3846 0.23358
Ipsilateral hydronephrosis 0.015*
Absence 290 0.3545 0.23248
Presence 374 0.3107 0.22461
Main tumor location 0.000*
Pelvic 368 0.3677 0.23324
Upper ureter 58 0.2914 0.22027
Middle ureter 68 0.2824 0.21644
Lower ureter 170 0.2800 0.21334
Transplant recipient 0.011*
No 653 0.3326 0.22861
Yes 11 0.1636 0.19117
MI =methylation index.
*Statistically significant.
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BRCA1 (P = 0.005), TMEFF2 (P = 0.003), and RASSF1A
(P = 0.037) was correlated with the age, gender, tumors
size, and mulifocality, respectively. Higher methylation
rate was present in nonsmoker than smokers for BRCA1
(P = 0.019) and SALL3 (P = 0.036). The sessile architec-
ture preponderance of methylation was seen in ABCC6
(P = 0.025), BRCA1 (P = 0.000), CDH1 (P = 0.001), HSPA2
(P = 0.014), RASSF1A (P = 0.045), and TSHB1 (P = 0.000),
while higher GDF15 (P = 0.002) methylation rate was seen
in UTUC with papillary architecture. Hypermethylation
was associated with advanced tumor grade for BRCA1
(P = 0.003), CDH1 (P = 0.002), HSPA2 (P = 0.009), RASSF1A
(P = 0.017), and THBS1 (P = 0.000), while methylated
GDF15 (P = 0.002) promoter was associated with low
tumor grade. Hypermethylation was associated with
advanced tumor stage for ABCC6 (P = 0.050), BRCA1
(P = 0.032), CDH1 (P = 0.004), GDF15 (P = 0.005), HSPA2
(P = 0.000), RASSF1A (P = 0.003), TSHB1 (P = 0.018), and
TMEFF2 (P = 0.002).
MI for UTUC
The MI based on the specific clinicopathological factor
is presented in Table 4. Higher MI was seen in tumors
with poorer prognostic factors, such as advanced grade
(P < 0.001), increased stage (P < 0.001), positive lymph
nodes (P = 0.014) or sessile architecture (P = 0.001). Lo-
wer MI was present in patients with hydronephrosis
(P = 0.015), tumor located in lower ureter (P < 0.001), or
those with history of renal transplantation (P = 0.011).
The MI of tumors with contralateral UTUC recurrence
was lower than for tumors without contralateral recur-
rence (P = 0.001). The median MI value was 0.3, and the
cohort was divided into a low-MI group (MI value ≤0.3)
and a high-MI group (MI value >0.3). Patients in the
high-MI group had a poor cancer-specific survival (CSS,
P = 0.007, Figure 1) than patients in the low-MI group.
Predictive factors of contralateral UTUC recurrence
Univariate analysis and multivariate analysis for contra-
lateral UTUC recurrence after RNU is summarized in
Tables 5 and 6, respectively. In multivariate analysis,
unmethylated RASSF1A (P = 0.039, Figure 2A), renal
transplant history (P < 0.001, Figure 2B), preoperative
renal insufficiency (P = 0.002, Figure 2C), and lack of
bladder recurrence before the development of contra-
lateral UTUC (P = 0.007, Figure 2D) were found to be
independent risk factors of contralateral UTUC recur-
rence after RNU.
Clinical characteristics of patients with contralateral UTUC
recurrence
Six patients were renal transplant recipients, and 25
patients had no bladder recurrence before developingcontralateral UTUC recurrence. Twenty-six patients were
treated surgically for the contralateral UTUC at our insti-
tute, 14 with contralateral RNU and the other 12 with
nephron-sparing treatment, including partial ureterec-
tomy in 7 cases and endoscopic ablation in 5 cases. The
other 4 patients with contralateral UTUC recurrence were
not treated surgically because of poor physical status.
Thirteen patients were confirmed to have taken Chinese
herbs containing aristolochic acid for at least 6 months, 2
patients denied consuming any herbs, and the other pa-
tients could not provide detailed information of the herbs
that they had taken. By the end of follow-up, there were
16 deaths in patients with contralateral UTUC recurrence,
Figure 1 Cancer-specific survival curves for MI.
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cancer-specific survival time after contralateral UTUC re-
currence was 60 months (95% CI 39–80).
Discussion
In the present study, we report a recurrence rate of
contralateral UTUC after nephroureterectomy of 4.5%,
which is similar to previous studies [3-12]. To our know-
ledge, this is the first study to investigate the predictive
role of aberrant methylation to predict contralateral
UTUC after RNU. Unmethylated RASSF1A, no bladder
recurrence before the development of contralateral UTUC,
renal transplant history, and preoperative renal insuf-
ficiency were independent risk factors for contralateral
UTUC recurrence after RNU.
The multifocality and recurrence of urothelial cancer
has been explained by two hypothesis. One is the field
cancerization hypothesis [25], in which independent
multiclonal tumor develops due to carcinogenic expo-
sure of entire urothelium. The alternative intraluminal
seeding hypothesis [26] indicates that intraluminal im-
plantation deriving from an initial clone of tumor cells
is the mechanism of multifocality or recurrence. The
field cancerization hypothesis theory may have a more
important effect on the development of contralateral
UTUC in this cohort for a few reasons. First, none of
our patients suffered from vesicoureteral reflux; although
some patients underwent ureteroscopy, no correlations
have been shown between ureteroscopy and contrala-
teral UTUC recurrence. Second, Chinese herbs con-
taining aristolochic acid are used nationwide, whichcould bring nephrotoxic and carcinogenic toxins to in-
duce neoplasms of the entire urothelial field [27]. Third,
patients with bladder recurrence demonstrated no trend
of developing contralateral UTUC.
RASSF1A, a member of RAS family of genes, is a puta-
tive tumor suppressor gene. Consistent with our results,
hypermethylation of RASSF1A is generally considered
to correlate with poor prognostic parameters, such as
advanced tumor grade or stage [13,14,28-31], muscle inva-
sion [14,31], and disease progression [13,28] in transitional
cell carcinoma. However, we also found that unmethylated
RASSF1A was an independent risk factor of contralateral
UTUC recurrence. In consistent with our result, Casadio
et al. [32] also found lower methylation in recurring versus
non-recurring patients in non muscle invasive bladder
cancer, with statistical significance for RASSF1A. This con-
cordance suggests a relationship between lower methyla-
tion of RASSF1A and recurrence of urothelial cancer. For
our results, we propose two possibilities to explain this
phenomenon. First, as hypermethylation of RASSF1A was
correlated with poor prognostic parameters, patients with
RASSF1A hypermethylation may die from tumor dissem-
ination before developing contralateral UTUC recurrence.
Second, aristolochic acid was proven to be associated with
UTUC [27]. In the current study, among all 30 patients
with contralateral UTUC recurrence, at least 13 patients
have taken Chinese herbs containing aristolochic acid for
more than 6 months. Combining these results, we believe
aristolochic acid-related UTUCs have the trend of de-
veloping the contralateral UTUC recurrence in this co-
hort. A previous study of UTUC in Balkan endemic
Table 5 Univariate analysis for contralateral UTUC
recurrence after RNU
Variable Univariate
Chi-square Pa
Gender 2.051 0.152
Age 2.256 0.112
Renal function 27.746 <0.001*
Side 0.140 0.708
Transplant recipient 74.902 <0.001*
Ipsilateral hydronephrosis 1.367 0.242
Smoke 0.063 0.802
Surgical approach 1.891 0.169
Tumor size 0.817 0.366
Architecture 0.737 0.391
Ureteroscopy 0.828 0.363
Location 2.015 0.569
Mulifocality 0.536 0.464
CIS 0.899 0.343
Bladder recurrenceb 4.612 0.032*
Tumor stage 1.104 0.776
Tumor grade 1.730 0.421
N status 0.230 0.631
Adjuvant therapy 0.015 0.902
ABCC6 1.963 0.161
BRCA1 0.226 0.634
CDH1 2.226 0.136
GDF15 1.077 0.299
HSPA2 0.084 0.772
RASSF1A 5.481 0.019*
SALL3 1.696 0.193
THBS1 2.971 0.085
TMEFF2 1.072 0.301
VIM 5.004 0.025*
MIc 3.918 0.048*
aKaplan Meier test was used for univariate analysis.
bOnly bladder recurrence before contralateral UTUC recurrence was analyzed.
c Because the MI correlated with methylation status of RASSF1A (r = 0.412,
P = 0.000) and VIM (r = 0.478, P = 0.000), the MI was not analyzed in the
multivariate models.
*Statistically significant.
Table 6 Multivariate analysis for contralateral UTUC
recurrence after RNU
Variable Multivariate
HR 95% CI P
Renal function 0.418 0.242-0.723 0.002*
Transplant recipient 20.914 8.208-53.284 <0.001*
Bladder recurrencea 0.258 0.097-0.691 0.007*
RASSF1A 0.218 0.051-0.927 0.039*
VIM 0.278
*Statistically significant.
aOnly bladder recurrence before contralateral UTUC recurrence was analyzed.
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to aristolochic acid use [33], revealed that a lower tumor
stage (pTa-pT1) and grade predominated among UTUC
patients from the endemic and adjacent but not the control
settlements from 1957–1986 [34]. This result suggests that
the aristolochic acid-related UTUCs may have lower
malignancy potential. Our results revealed unmethylated
RASSF1A was more prevalent in UTUCs with lower
malignancy potential. Unmethylated RASSF1A maycorrelated with aristolochic acid-related UTUCs. Hence,
unmethylated RASSF1A seemed to correlate with the
development of contralateral UTUC recurrence. The role
of RASSF1A methylation in the recurrence of urothelial
cancer, and the relationship between RASSF1A and
aristolochic acid related urothelial cancer require further
research.
Consistent with previous study [13,14], we found the
similarity that higher MI were more prevalent in tumors
with poor prognostic parameter. Higher MI was also found
to be correlated with poor CSS. Lower MI (P = 0.001) were
seen in the tumors with contralateral UTUC recurrence
than the tumors without contralateral recurrence. More
cancer-specific death before the development of contra-
lateral UTUC could explain the result. In addition, aristo-
lochic acid-related UTUCs may have lower MI due to the
characteristics of lower malignancy potential, which could
be another potential reason for contralateral UTUC recur-
rence with lower MI as aristolochic acid was extremely
likely involved in the development of contralateral UTUC
in this cohort.
Lack of bladder recurrence before the contralateral
UTUC recurrence was associated with the development
of contralateral UTUC. Two previous studies presented
that the history of bladder tumor was associated with
the development of contralateral UTUC after surgery
[5,6]. However, the patients with bladder tumors prior to
the first UTUC were not excluded in these studies.
Although both derive from the urothelial cell, UTUC
and bladder cancer exhibit biological and behavioral dif-
ferences [35]. In the current study, we exclude patients
with concomitant or previous bladder tumors before
RNU. Although data are limited, of the 223 patients
developing bladder recurrence, at least 156 patients
(70.0%) received intravesical instillation with epirubicin
or pirarubicin, which may have reduced the incidence of
contralateral UTUC recurrence.
Consistent with our previous study [3], renal trans-
plant recipient history and preoperative renal insuffi-
ciency correlated with contralateral UTUC recurrence
even after expanding the sample size and introducing
Figure 2 Estimated contralateral UTUC-free Kaplan-Meier survival curves stratified by methylation status of RASSF1A (A, P = 0.019),
renal transplant history (B, P < 0.001), preoperative renal function (C, P < 0.001), bladder recurrence (D, P = 0.032).
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our research continues to provide strong evidence that
for patients with renal transplant or with renal insuffi-
ciency who would likely require dialysis, prophylactic
RNU is a reasonable choice after first RNU for unilateral
UTUC.
There are several strengths to our study. To our know-
ledge, we are the first group to investigate the correla-
tion between gene methylation and contralateral UTUCrecurrence after RNU. Our results could conceivably
help tailor surveillance and adjuvant treatment. Second,
we attempted to homogenize our cohort and thereby
decrease treatment bias by applying strict inclusion
criteria and minimizing differences in inter-operator sur-
gical technique. Third, we provide a support that intrave-
sical instillation with epirubicin or pirarubicin after RNU
may reduce the incidence of contralateral UTUC recur-
rence. Finally, we once again confirmed strong evidence
Zhang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:5 Page 10 of 11supporting prophylactic contralateral nephroureterectomy
for end-stage renal failure and renal transplant recipient
patients.
Our study nonetheless exhibits several limitations. Our
study is limited by the inherent limitations of a retro-
spective approach, including selection bias and incom-
plete information of some valuable variables such as the
consumption of Chinese herbs for all patients. Additio-
nally, the relative short follow-up duration may not reveal
accurate outcomes on survival analysis. The lack of rele-
vant gene methylation function analysis further reduces
the strength of this study. Additional studies including
gene methylation function analysis and investigations on
the correlation between methylation and aristolochic acid-
related UTUCs are necessary.
Conclusions
Contralateral metachronous UTUC after RNU is rela-
tively rare. Our data suggest a potential role of DNA
methylation in predicting contralateral UTUC recur-
rence after RNU. Unmethylated RASSF1A, no bladder
recurrence prior to contralateral UTUC, history of renal
transplantation, and preoperative renal insufficiency are
independent risk factors of contralateral UTUC recur-
rence after RNU. For patients with such factors, follow
up should be arranged closely, and examination of de-
veloping contralateral UTUC is necessary. Prophylactic
contralateral nephroureterectomy is a reasonable choice
for UTUC patients with renal transplant or end-stage
renal failure.
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